(degree and duration of gluten restriction or dapsone/sulfapyridine dose); however, future studies should attempt to correlate levels of IgA anti-eTG with parameters of disease activity, including degree and duration of gluten restriction, and dapsone/sulfapyridine dose. The patient presented in Table 2 shows that the levels of each Ab assay decreases over time with adherence to a gluten-free diet. Although definitive conclusions cannot be made from one patient, these results suggest that the levels of IgA against eTG correlate with dietary gluten intake. Prospective studies should be designed to evaluate the levels of IgA anti-eTG in DH patients over time after initiation of a gluten-free diet.
IgA anti-eTG was present in only 11.1% of pediatric CD, which is significantly lower than that reported in adult CD (B50%) (Hull et al., 2008) . These results are similar to our previously published data showing a low prevalence of IgA anti-eTG in pediatric CD patients. This occurred in the setting of significantly elevated concentrations of IgA anti-tTG (90.7%). The majority of the six pediatric CD patients with IgA anti-eTG þ results showed low titers (13, 13, 14, 15, 20, and 96 Units) and all were duodenal biopsy positive (1 of 18 Marsh 3a (5.6%), 1 of 15 Marsh 3b (6.7%), and 4 of 16 Marsh 3c (25.0%)). All six pediatric CD patients were also positive for IgA anti-tTG (6 of 6), for IgA anti-deamidated gliadin peptides (6 of 6), and for IgG antideamidated gliadin peptides (5 of 6). We will follow-up pediatric CD patients with IgA anti-eTG þ results to find out whether they develop symptoms of DH.
In conclusion, IgA anti-eTG was more sensitive in detecting DH than any other marker associated with gluten-sensitive enteropathy and its prevalence is significantly lower in pediatric CD than that which has been reported in adult CD. In a patient suspected of having DH, the present data support testing for IgA anti-eTG, which may help in screening and monitoring the response to a gluten-free diet. We then recommend a biopsy of uninvolved, perilesional skin in an area of grouped vesicles or erosions for direct immunofluorescence, which is the gold standard for diagnosis. TO THE EDITOR Lentigo simplex (LS) is a benign skin lesion preferentially observed in younger people, although it may occur at any age. The lesion measures a few millimeters in diameter, is brown to black, and is clinically indistinguishable from a melanocytic nevus. Histopathologically, LS shows a moderate elongation of the epidermal rete ridges and basal hyperpigmentation. The number of melanocytes in the basal epidermal layer may be slightly increased. In contrast to LS, solar lentigo displays markedly elongated rete ridges and profound actinic elastosis in the dermis. It has been proposed that LS may evolve into a lentiginous/junctional melanocytic nevus when melanocytes start proliferating and aggregating to form small nests in the junctional zone, whereas solar lentigo may be a precursor lesion of seborrheic keratosis (Ackerman and Ragaz, 1984) . In the past few years, it has become well known that melanocytic nevi frequently show the BRAF V600E hotspot mutation (Pollock et al., 2003) . The genetic basis of LS, however, remains unknown.
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To investigate a possible common genetic background of LS and melanocytic nevi, we analyzed both LS and melanocytic nevi for the BRAF V600E mutation. We retrieved 58 LS samples (from 30 males, 28 females; mean age 34.6 years) and 46 melanocytic nevi (from 21 males, 25 females; mean age 38.7 years) from the histological files of the Department of Dermatology at the University of Regensburg, Germany. The characteristics of the patients and lesions are shown in Table 1 . Written, informed consent was obtained from all patients according to the guidelines of the local ethics committee and the Declaration of Helsinki, and the study was approved by the ethics committee of the University Clinic of Regensburg. The samples were manually microdissected from formalin-fixed paraffinembedded material, and DNA was isolated using standard protocols. For the analysis of the BRAF V600E hotspot mutation, a highly sensitive allele-specific PCR (PCR amplification of specific alleles, PASA) was used as described previously (Stoehr et al., 2004) . None of the 58 LS specimens exhibited the BRAF V600E mutation (Table 1, Figure 1a ). The HT29 colon carcinoma cell line with a known BRAF V600E mutation was used as a positive control to exclude false-negative results. Furthermore, we screened 46 melanocytic nevi (9 lentiginous, 3 junctional, 11 compound, and 23 dermal nevi) for the BRAF hotspot mutation, which could be detected in 26/46 (57%) of the nevi. Interestingly, the V600E mutation was present in only 17% of the lentiginous/ junctional nevi, whereas 55% of the compound nevi and 78% of the dermal nevi revealed this hotspot mutation (Figure 1b) . The difference in the BRAF V600E mutation frequency between LS and melanocytic nevi was highly significant (Po0.001; Fisher's exact test).
Because most of the patients in the investigated cohort originated from southeastern Germany, we cannot exclude the possibility that a different genetic population would show varying results. Because solar lentigos and seborrheic keratoses display FGFR3 and PIK3CA mutations (Hafner et al., 2007 ), we also analyzed these genes in LS lesions and melanocytic nevi. FGFR3 mutations were analyzed using a multiplex SNaPshot (Applied Biosystems, Foster City, CA) assay covering 11 point mutations (R248C, S249C, G372C, S373C, Y375C, G382R, A393E, K652E, K652M, K652Q, and K652T) that had previously been described in skin tumors (Hafner et al., 2006) . For the detection of four PIK3CA hotspot mutations (E542K, E545K, E545G, and H1047R), a recently developed PIK3CA SNaPshot assay was used (Hurst et al., 2009) . None of the 58 LS lesions or the 46 melanocytic nevi displayed an FGFR3 or a PIK3CA point mutation (Table 1) .
Our results indicate that the BRAF V600E hotspot mutation is not involved in the pathogenesis of LS. In contrast, 33% of PUVA (psoralen plus UVA) lentigines showed this mutation in a previous report (Lassacher et al., 2006) . Melanocytic nevi harbor BRAF mutations very frequently, with a reported range of 20-80% (Thomas, 2006) . In our study, the BRAF V600E mutation was present in 57% of the melanocytic nevi. BRAF mutations are thought to stimulate the proliferation of melanocytes in nevi and melanomas. It has been proposed that a further proliferation of the melanocytes in LS may result in the formation of melanocytic cell nests and subsequently in a lentiginous or junctional melanocytic nevus. In this case, LS would represent a precursor lesion of melanocytic nevi (Ackerman and Ragaz, 1984) . However, we found no BRAF V600E mutations in LS, indicating that this benign lesion does not share a common genetic background with melanocytic nevus. This finding could be explained in two ways: (i) LS is not a precursor lesion of melanocytic nevus and instead represents an independent benign skin tumor or (ii) LS is a precursor lesion of melanocytic nevus, but the BRAF V600E mutations occur late in this lentigo-nevus sequence. The latter would be congruent with the observed trend in this study that the frequency of BRAF V600E mutations increased from lentiginous/junctional nevi to compound and dermal nevi, implying that BRAF mutations occur during the proposed progression from junctional to compound and dermal nevus rather than from LS to junctional nevus. However, the differences between the types of melanocytic nevi were not statistically significant, which may be attributable to the small sampling size of the melanocytic nevus subgroups. LS must also be discriminated from solar lentigo. We analyzed a possible common pathogenetic background of both lesions. Although solar lentigos display FGFR3 and PIK3CA mutations and therefore share a common genetic basis with seborrheic keratoses, the LS in our study did not show any of these mutations. There has been a report of an H1047R PIK3CA mutation in one LS sample, which was included in a large mutation profiling study of various tumors (Thomas et al., 2007) . This H1047R mutation was also covered by the PIK3CA SNaPshot assay used in our study, but we could not detect any PIK3CA mutations in LS. Our results suggest that PIK3CA hotspot mutations do not play a major role in the pathogenesis of LS. The lack of FGFR3 and PIK3CA mutations in LS implies that this lesion has a different genetic background from that of solar lentigo and seborrheic keratosis.
Therefore, we have shown that the absence of BRAF, FGFR3, and PIK3CA mutations can clearly differentiate LS from melanocytic nevi and solar lentigos. The results furthermore indicate that LS has a distinct yet unknown genetic basis, which does not necessarily exclude the proposed lentigo-nevus sequence. Frequency of the BRAF V600E mutation Figure 1 . BRAF V600E mutation analysis. (a) Analysis of the BRAF V600E hotspot mutation using PCR amplification of specific alleles (PASA). We analyzed lentigo simplex (LS) and melanocytic nevi (MN). For each lesion, two PCRs were performed; one using a wild-type (wt) primer for codon 600 (top), the other V600E mutation-specific primers (bottom). The PCR products were visualized on an agarose gel (160 bp). Because the mutations are heterozygous, each sample displayed the BRAF wt allele. An additional band in the second PCR, with the V600E-specific primer, indicates a V600E mutation. The LS did not show any BRAF mutations, in contrast to some MN. (b) The frequency of the BRAF V600E mutation increased continuously from LS to dermal melanocytic nevus. The difference between LS lesions and lentiginous/ junctional melanocytic nevi (Po0.05), as well as that between LS and all melanocytic nevus types together (Po0.001), was significant (Fisher's exact test). CMN, compound melanocytic nevus; DMN, dermal melanocytic nevus; JMN, junctional melanocytic nevus; LMN, lentiginous melanocytic nevus; N, negative control (cell lines HZT or RT4); P, positive control (cell line HT29); S, standard; W, H 2 O control.
